EnRhythm
Pacing System
enrhythm_device_large

EnRhythm Pacing System

The first-ever pacemaker to include Managed Ventricular Pacing (MVP®), the EnRhythm Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary right ventricular pacing1.

How the EnRhythm Pacing System Works

MVP Mode 

MVP mode

A New Era in Physiologic Pacing

The first-ever pacemaker to include Managed Ventricular Pacing (MVP®), the EnRhythm® Pacing System promotes intrinsic conduction and is clinically proven to significantly reduce unnecessary right ventricular (RV) pacing.1

Important Safety Information

Changes in a patient's disease and/or medications may alter the efficacy of a device's programmed parameters or related features.

MVP – Promotes Intrinsic Conduction

Managed Ventricular Pacing (MVP®) provides opportunity for your patient to conduct intrinsically while providing backup pacing if needed.2

  • Promotes intrinsic conduction
  • Significantly reduces unnecessary right ventricular pacing1,3
  • Primarily operates in AAI(R) pacing mode while providing the safety of dual chamber backup pacing support if necessary
  • In the EnRhythm clinical trial, MVP Mode reduced right ventricular pacing to 1.6% (median) in all pacing indicated patients, including patients with advanced heart block. MVP Mode reduced right ventricular pacing to 0.5% (median) when patients with persistent 2nd and 3rd degree AV block were excluded.4

Cardiac Compass – More Than a Year of Cardiac Insight

Diagnostic information helps you monitor the effectiveness of patient therapies:

  • Cardiac Compass® graphically displays more than a year’s worth of a patient's clinical progress
  • Displays total amount of atrial and ventricular pacing
  • Provides information on AF burden for assessment of rhythm control
  • Displays ventricular rate during AT and AF episodes for assessment of rate control
  • Graphically displays patient’s average day and night ventricular rates, daily activity and monthly heart rate variability for detecting signs of worsening heart failure
  • Stores up to 16.5 minutes of dual channel EGM with filtering capability
  • Includes histograms containing “Prior to Last Session” and “Since Last Session” data to make medical therapy or device programming changes and confirm if previous changes have been effective

Reactive Atrial ATP – More Opportunities to Restore Sinus Rhythm

Reactive Antitachycardia Pacing (ATP) Therapies and Intervention Algorithms for atrial tachyarrhythmias offer your patient more opportunities to restore and maintain sinus rhythm.

  • ATP quickly delivers painless therapies to the right atrium to restore sinus rhythm5,6 
  • 54% of device-defined atrial tachyarrhythmias are pace terminable5
  • Reactive ATP™ continuously monitors and responds to changes in the rate or regularity of AT episodes, and appropriately delivers atrial ATP therapies
Ecg strip of atrial ATP being delivered

ECG strip of atrial ATP being delivered

Reactive ATP allows for multiple deliveries of programmed ATP Therapies for longer atrial episodes in response to two clinically relevant events:

References

  1. Gillis AM, et al. Reduction of Unnecessary Right Ventricular Pacing due to the Managed Ventricular Pacing (MVP) Mode in Patients with Symptomatic Bradycardia: Benefit for Both Sinus Node Disease and AV Block Indications. HRS. 2005 Abstract; AB21-1.
  2. EnRhythm Device Manual
  3. Sweeney M, Shea J, Fox V, et al. Randomized pilot study of a new atrial-based minimal ventricular pacing mode in dual-chamber implantable cardioverter-defibrillators. Heart Rhythm. 2004;1:160-167.
  4. Medtronic EnRhythm Clinical Study, data on file.
  5. Lee M, Weachter R, Pollack S, et al. The effect of atrial pacing therapies on atrial tachyarrhythmia burden and frequency. J Am Coll Cardiol. 2003;41:1926-1932.
  6. Israel C. Success rate of automatic atrial antitachycardia pacing by a pacemaker implanted in patients with paroxysmal and persistent atrial tachyarrhythmia. Circulation. 2000;102(Supp II, No. 18). Abstract 3454.

Specifications

Volume13 cm3
Mass21 g
H x W x Da45 mm x 51 mm x 8 mm
Radioplaque IDPNP
Materials in contact with human tissuebTitanium, polyurethane, silicone rubber
BatteryLithium silver vanadium oxide hybrid

a Grommets may protrude slightly beyond the can surface.
b These materials have been successfully tested for the ability to avoid biological incompatibility. The device does not produce an injurious temperature in the surrounding tissue during normal operation.

10.5 year longevity*

* Based on 100 pacing, 60 bpm, 0.4 ms, 2.5 V, 500 ohm impedance, pre-arrhythmia detection, EGM storage Off. With MVP pacing mode (50% A-pacing and 5% V-pacing) an estimated two additional years of longevity may be achieved. Refer to EnRhythm System Reference Manual for complete details.

References

  1. Gillis AM, et al. Reduction of Unnecessary Right Ventricular Pacing due to the Managed Ventricular Pacing (MVP) Mode in Patients with Symptomatic Bradycardia: Benefit for Both Sinus Node Disease and AV Block Indications. HRS. 2005 Abstract; AB21-1.
Last updated: 22 Sep 2010

Medtronic Manual Library

manuals-medtronic-com

Find instructions for use and product manuals.

More

Medtronic Academy

Medtronic Academy

Access a wide range of interactive courses, case studies, videos and presentations.

More

Medtronic 24-Hour Support
(800) 505-4636